-logo-1200x675.png?v=20240604134456){kind=logo}
Elekta AB (OTCMKTS:EKTAY – Get Free Report) was the target of a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 669 shares, a decrease of 53.3% from the April 15th total of 1,433 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 1,312 shares, the days-to-cover ratio is presently 0.5 days.
Elekta Stock Performance
OTCMKTS:EKTAY remained flat at $6.05 during trading on Friday. The company’s stock had a trading volume of 84 shares, compared to its average volume of 620. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -603.96 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.73 and a current ratio of 0.95. The company has a 50 day simple moving average of $6.01 and a 200 day simple moving average of $5.90. Elekta has a 52-week low of $4.35 and a 52-week high of $6.93.
Elekta (OTCMKTS:EKTAY – Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The company reported $0.09 earnings per share (EPS) for the quarter. The firm had revenue of $433.29 million during the quarter. Elekta had a positive return on equity of 12.84% and a negative net margin of 0.08%. Equities research analysts forecast that Elekta will post 0.39 earnings per share for the current fiscal year.
About Elekta
Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.
The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.
Recommended Stories
- Five stocks we like better than Elekta
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
- 3 AI Data Center Stocks Worth Watching for Capital Rotation
Receive News & Ratings for Elekta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elekta and related companies with MarketBeat.com's FREE daily email newsletter.
